Leptomeningeal Disease clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Sorry, in progress, not accepting new patients
A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.
at UCSF
Our lead scientists for Leptomeningeal Disease research studies include Michelle Melisko.
Last updated: